EMA Withdrawn: Ciambra (pemetrexed disodium hemipentahydrate) — Menarini International Operations Luxembourg S.A.

View source ↗

Summary

EMA withdrew Ciambra (pemetrexed disodium hemipentahydrate) from the European market on 17 August 2022, with indications for non-small cell lung cancer and mali…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Mesothelioma
• Non-small Cell Lung Cancer

Drugs mentioned

• Ciambra (pemetrexed disodium hemipentahydrate)

Snippet

Status: Withdrawn. Therapeutic area: Carcinoma, Non-Small-Cell Lung;Mesothelioma. MAH: Menarini International Operations Luxembourg S.A.. Decision date: 17/08/2022